Japan at a glance
- Population
- 123.4 million 2025
- Life expectancy at birth
- 84.0 years, 2024
- People aged 65 and over
- 30.0 % of people, 2025
- Health spending per person
- 3,638 US$ per person, 2023
- Doctors
- 2.65 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Japan Veterinary Drugs Market Industry Trends and Forecast to 2034: Segmented by (Product, Animal, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$2.77 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.76 Bn | — | — |
| 2025 (base) | $2.97 Bn | +$209.6 Mn | — |
| 2026 (forecast) | $3.19 Bn | +$225.5 Mn | +7.6% |
| 2027 (forecast) | $3.44 Bn | +$242.6 Mn | +15.8% |
| 2028 (forecast) | $3.70 Bn | +$261.1 Mn | +24.6% |
| 2029 (forecast) | $3.98 Bn | +$280.9 Mn | +34% |
| 2030 (forecast) | $4.28 Bn | +$302.3 Mn | +44.2% |
| 2031 (forecast) | $4.60 Bn | +$325.2 Mn | +55.2% |
| 2032 (forecast) | $4.95 Bn | +$349.9 Mn | +67% |
| 2033 (forecast) | $5.33 Bn | +$376.5 Mn | +79.7% |
| 2034 (forecast) | $5.74 Bn | +$405.2 Mn | +93.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.97 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $5.74 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product and animal (see all) |
| Key players | Zoetis, Inc, Elanco, Merck & Co., Inc., Boehringer Ingelheim GmbH, Ceva Sante Animale and 1 more (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Veterinary drugs are the medicines given to pets and farm animals to treat or prevent disease and pain.
Key segments of the veterinary drugs market include product (Anti-Infectives, Anti-Parasitics and Anti-Inflammatories) and animal (Dogs, Cats and Cattle).
More pet ownership, spending on pet care, rising demand for meat and milk, and concern about animal disease are driving the veterinary drugs market.
Long-acting treatments, tests that find disease early and growing pet spending in emerging countries give the veterinary drugs market room to grow.
Rules on antibiotic use in farm animals, high drug prices for pet owners and shortages of vets in rural areas hold back the veterinary drugs market.
The veterinary drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for veterinary drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
What doctors and scientists are doing in Veterinary Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.
Japan · 3 shared keywords
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
OTC & Nutraceuticals · Japan
Healthcare Services · Japan
Medical Devices · Japan
Digital Health · Japan
Healthcare Services · Japan
Public Health · Global